A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

NCT07676890 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
mRNA Vaccine

Interventions

DRUG: Low Dose NeoOVIV
DRUG: Medium dose NeoOVIV
DRUG: High dose NeoOVIV

Sponsor

West China Hospital